ContraVir Enrolls First Patient in Pivotal Phase 3 Study of FV-100 for Treating Shingles, Shingles-Associated Pain
August 03, 2015 at 06:05 AM EDT
ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV) announced today that the first patient has been enrolled in the Company's pivotal Phase ...
